Scientists at a U.S. Army research center have modified an assay that tests whether or not a sample of mosquitoes harbors the virus responsible for the disease known as chikungunya (CHIKV), long a problem in the Old World tropics but recently established in the Americas.
They did not make the assay — a commercial company called VecTOR Test Systems, Inc. did. Instead, the Army researchers tested the test to prove that it works — no small task when dealing with a virus that comes in multiple guises. Their assay is described in an article in the Journal of Medical Entomology.
Health workers now have what the scientists call a “quick and dirty” way to detect the presence of the CHIKV virus within an hour, rather than waiting for results of laboratory tests that take days, even weeks. It’s done with a chemical dipstick, the same kind of simple tool used in a pregnancy test. If the test is positive, measures to control and contain the disease can be mobilized and started immediately, which is important because no vaccine or specific treatment for chikungunya exists.
Evaluation was carried out under epidemiologist Michael J. Turell, PhD, a principal investigator for 30 years at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick, Maryland. Turell’s research has focused on factors impacting the ability of mosquitoes to transmit various arboviruses, a term for viruses transmitted by arthropods such as mosquitoes, sandflies, and ticks. In addition, he has worked on the development of vaccines for several mosquito-borne viruses and on assays that detect arboviruses.
The larvae of mosquitoes that transmit CHIKV find excellent harborage in containers that hold standing water, such as spare tires, empty pails, and saucers under flower pots. Thus, the mosquitoes involved prosper among high concentrations of people. People living in tropical shanty towns, with open windows and no air conditioning, are prime targets.
“Chikungunya” is a term used by people of the Makonde Plateau, between Tanzania and Mozambique, where the disease was discovered in 1952. It means, “that which bends up,” referring to the way arthritis caused by the disease crooks posture of the victim’s body. Symptoms of chikungunya can be as brutal as its name is to pronounce, although it is seldom fatal. Victims experience fever and pain and swelling of muscles and joints. Headache and rash may occur. The disabling impact can last for months.
The chikungunya virus belongs to a group known as alphaviruses, at least 30 of which can infect humans and other vertebrates, causing diseases such as equine encephalitis and a variety of rash-accompanied fevers. CHIKV is transmitted by mosquitoes of the genus Aedes, chiefly Aedes aegypti, the bane of humans in the tropics because it also carries viruses responsible for yellow fever and dengue fever. Scientists have identified three different lineages — genetically-related groups — of CHIKV linked to geographical areas: Asia, West Africa, and East/Central/South Africa. All of the lineages exist outside the geographical areas after which they are named. A member of the Asian lineage, for example, has infected people in the Americas.
Like many tropical diseases, chikungunya has been rampant in the developing world for many years, but only became the focus of intensive research after it threatened western nations. An outbreak on Reunion Island, a French Department in the Indian Ocean, during 2005 and 2006 attracted attention largely because it’s a hot tourist destination for Europeans. Perhaps not by coincidence, the first transmission from mosquitoes in the Americans occurred in December 2013, on the French half of St. Martin, and island in the Caribbean. Reported cases in the Americas have now passed 1.5 million.
It began to show up in the United States during 2014, with nearly 2,500 cases reported from 46 states. Nearly all, however, were in travelers who picked up the infection in the tropics. Eleven people on the U.S. mainland, all in South Florida, contracted the disease directly from mosquitoes in the U.S.
The Latest on: Chikungunya
via Google News
The Latest on: Chikungunya
- Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesison October 16, 2021 at 2:42 pm
We evaluated the mechanism by which neutralizing human monoclonal antibodies inhibit chikungunya virus (CHIKV) infection. Potently neutralizing antibodies (NAbs) blocked infection at multiple steps of ...
- Emergent BioSolutions Begins Dosing in Chikungunya Vaccine Trialon October 15, 2021 at 3:42 am
By Matt Grossman Emergent BioSolutions Inc. has dosed the first patient in a Phase 3 study testing its vaccine candidate for chikungunya virus.
- Mumbai: Chikungunya cases in city surge by 78.75%on October 14, 2021 at 2:44 pm
There has been a 78.75 per cent surge in the number of chikungunya cases in the last four years across Maharashtra. According to the statistics, there were 1,026 chikungunya cases in 2018 which has ...
- Co-infections with Chikungunya Virus and Dengue Virus in Delhi, Indiaon October 14, 2021 at 10:59 am
Aedes aegypti mosquitoes are common vectors for dengue virus and chikungunya virus. In areas where both viruses cocirculate, they can be transmitted together. During a dengue outbreak in Delhi in 2006 ...
- Brazil: Paraná state reports first chikungunya cases in Rondonon October 14, 2021 at 6:31 am
By NewsDesk @bactiman63 The Paraná State Department of Health (Sesa) reported yesterday in it’s arbovirus epidemiological report the first locally transmitted chikungunya cases of the current ...
- The Chikungunya Rapid Testing Market To Be Directed By Discreteness Towards Growthon October 11, 2021 at 3:50 pm
According to the latest research by Persistence Market Research, chikungunya rapid testing market is set to witness 7.4% growth during the year 2021-2031. The growth will be seen due to the rising ...
- A Phase 3 Safety, Immunogenicity, Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP)on October 7, 2021 at 5:00 pm
A Phase 3 Safety, Immunogenicity, Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 - Full Text View.
- NMC starts 2 helpline numbers for dengue, chikungunya querieson October 7, 2021 at 3:54 pm
Nashik: The Nashik Municipal Corporation (NMC) has introduced two helpline numbers — 0253-2317292 and 9607432233 — to help citizens with issues relate.
- Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for Dengue/Chikungunya Multiplex Teston October 6, 2021 at 8:07 am
(Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ...
- Co-Diagnostics says its CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Teston October 6, 2021 at 7:59 am
CEO Dwight Egan said the test built on "our our highly-specific, patented CoPrimer technology has been approved to differentiate between these ...
via Bing News